ALPHAMAB-B (09966.HK): Wu Jiajun appointed CFO
- Wu Jiajun becomes chief financial officer, overseeing capital markets strategy, investor relations and industry competitive analysis.
- He is a CFA charterholder with an MBA from the University of British Columbia and a pharmaceutical sciences degree; Wang Fei resigned.
NewTimeSpace News: On 12 November 2026, Alphamab Oncology (stock code: 09966) appointed Mr. Wu Jiajun as chief financial officer, responsible for capital markets strategy, investor relations and industry competitive analysis. He has extensive experience in capital markets, securities research and financing. Before joining, he was head of investor relations and capital strategy at HUTCHMED (China) Limited (stock code: 13) and won two Extel Asia investor relations awards.
He was previously chief financial officer of a private Suzhou-based companion diagnostics company and spent over 20 years in sell-side research at UBS, Morgan Stanley, BOCI and Paradigm Capital. Mr. Wu is a CFA charterholder with an MBA from the University of British Columbia and a degree in pharmaceutical sciences.
The board also said Mr. Wang Fei resigned as chief financial officer for other work commitments, with no disagreement and no matter requiring notice to the Exchange or shareholders.
- ALPHAMAB-B (09966.HK) JSKN021 bispecific ADC cleared by FDA for Phase I
- ALPHAMAB-B (09966.HK) JSKN033 doses first patient in Phase III cervical cancer study
- ALPHAMAB-B (09966.HK): JSKN003 data at ESMO 2026, Cohort B ORR 100%, PROC median OS 23.5 months
- ALPHAMAB-B (09966.HK): JSKN033 cervical cancer Phase I/II data at ESMO 2026, ORR 41.9%
- ALPHAMAB-B (09966.HK): Anbenitamab Phase III data at ESMO 2026, first-line breast cancer risk cut 54%
